Astel­las taps Po­sei­da for sec­ond CAR-T deal fo­cused on sol­id tu­mors

Astel­las Phar­ma is sign­ing Po­sei­da Ther­a­peu­tics to a sec­ond deal fo­cused on de­vel­op­ing off-the-shelf sol­id tu­mor cell ther­a­pies af­ter the com­pa­nies first teamed up in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.